CryoLife, Inc. (NYSE:CRY) CAO Amy Horton sold 4,000 shares of the business’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $19.00, for a total value of $76,000.00. Following the transaction, the chief accounting officer now directly owns 98,705 shares of the company’s stock, valued at approximately $1,875,395. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of CryoLife, Inc. (NYSE CRY) opened at $19.05 on Tuesday. The firm has a market capitalization of $623.98, a P/E ratio of 45.49 and a beta of 0.82. CryoLife, Inc. has a 12-month low of $14.02 and a 12-month high of $24.00. The company has a debt-to-equity ratio of 0.29, a current ratio of 5.96 and a quick ratio of 4.90.

CryoLife (NYSE:CRY) last released its earnings results on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.08. The company had revenue of $44.00 million during the quarter, compared to the consensus estimate of $44.60 million. CryoLife had a return on equity of 6.43% and a net margin of 5.28%. CryoLife’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.13 EPS. analysts expect that CryoLife, Inc. will post 0.28 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/11/14/cryolife-inc-cry-cao-amy-horton-sells-4000-shares-of-stock.html.

CRY has been the subject of several recent analyst reports. Lake Street Capital boosted their price objective on CryoLife to $26.00 and gave the stock a “buy” rating in a report on Wednesday, October 11th. Canaccord Genuity reissued a “buy” rating and set a $25.00 price objective on shares of CryoLife in a report on Monday, October 9th. Northland Securities reissued a “buy” rating and set a $23.50 price objective on shares of CryoLife in a report on Monday. TheStreet lowered CryoLife from a “b” rating to a “c+” rating in a report on Monday, October 30th. Finally, Zacks Investment Research raised CryoLife from a “sell” rating to a “hold” rating in a report on Monday, August 14th. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. CryoLife presently has an average rating of “Hold” and an average price target of $23.63.

A number of large investors have recently added to or reduced their stakes in the stock. Louisiana State Employees Retirement System lifted its position in CryoLife by 0.9% in the 2nd quarter. Louisiana State Employees Retirement System now owns 11,100 shares of the medical equipment provider’s stock worth $221,000 after buying an additional 100 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its position in CryoLife by 3.2% in the 1st quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 190 shares during the last quarter. Creative Planning lifted its position in CryoLife by 3.0% in the 2nd quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock worth $136,000 after buying an additional 200 shares during the last quarter. Arizona State Retirement System lifted its position in CryoLife by 1.4% in the 2nd quarter. Arizona State Retirement System now owns 14,254 shares of the medical equipment provider’s stock worth $284,000 after buying an additional 200 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its position in CryoLife by 0.9% in the 2nd quarter. Wells Fargo & Company MN now owns 31,313 shares of the medical equipment provider’s stock worth $624,000 after buying an additional 271 shares during the last quarter. Institutional investors own 70.34% of the company’s stock.

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Insider Buying and Selling by Quarter for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.